Mesoblast (ASX:MSB) And Cephalon (NASDAQ:CEPH) Alliance Highlighted At JP Morgan Healthcare Conference

Melbourne, Jan 12, 2011 AEST (ABN Newswire) - The strategic alliance between regenerative medicine company, Mesoblast Limited (ASX:MSB) (PINK:MBLTY), and global biopharmaceutical company, Cephalon Inc. (NASDAQ:CEPH), was highlighted at the 29th annual JP Morgan Healthcare Conference in San Francisco yesterday.

Cephalon CEO J. Kevin Buchi focused on the companies' strategy to develop and commercialize Mesoblast's Mesenchymal Precursor Cell (MPC) therapeutics for degenerative conditions of the cardiovascular and central nervous systems as well as for hematopoietic stem cell transplantation in cancer patients.

Mr Buchi told the conference that the alliance with Mesoblast provided Cephalon with "a cutting-edge entry into regenerative medicine."

"It is an opportunity to deliver a profoundly beneficial treatment to patients with high unmet medical needs with a product that we believe has solid intellectual property and a long life cycle."

Following is a copy of the slides focusing on the most recent clinical results from Mesoblast's cardiovascular and bone marrow transplant trials: http://www.abnnewswire.net/media/en/docs/64968-ASX-MSB-348720.pdf

Contact

Mesoblast: Julie Meldrum Corporate Communications Director T: +61-3-9639-6036 C: +61-419-228-128 Email:julie.meldrum@mesoblast.com